Beyond satisfaction scores: quantifying communication quality in oncology care | Prostate Cancer and Prostatic Diseases
Beyond satisfaction scores: quantifying communication quality in oncology care | Prostate Cancer and Prostatic Diseases
The Persuasion Problem: Why Your Urologist Won't Quantify Side Effects
How financial incentives and training bias distort shared decision-making in prostate cancer care
Bottom Line Up Front:
The Evidence: Persuasive Language Is Real and Documented
In 2024, Naser-Tavakolian and colleagues at Cedars-Sinai published an analysis of how physicians communicate risk during prostate cancer treatment consultations. The headline finding was devastating: physicians use linguistically distinct framing patterns that align with their own treatment preferences and financial incentives. This isn't speculation. They coded actual consultation transcripts and identified specific linguistic patterns.
The mechanism is straightforward. A surgeon's recommendation depends on performing surgery. A radiation oncologist's recommendation depends on delivering radiation. A medical oncologist's recommendation depends on systemic therapy. Each specialty makes money from their modality. Each specialty therefore has a financial incentive to frame data in ways that make their treatment look better and alternatives look worse.
But financial incentive alone doesn't explain this. Training culture does. Surgical training emphasizes cancer control and cure. Radiation training emphasizes dose escalation and normal-tissue sparing. Medical oncology training emphasizes systemic disease burden. These are not neutral framings of the same disease—they are competing narratives, each psychologically engineered to make one choice seem obviously correct.
Persuasive language in medical consultations typically works through three mechanisms:
- Selective emphasis: Mentioning data that favors your recommendation while omitting data that doesn't (e.g., citing cancer control rates without citing quality-of-life trade-offs)
- Temporal framing: Emphasizing short-term benefits of your treatment while emphasizing long-term harms of alternatives (e.g., "radiation has great short-term side effects" vs. "surgery has permanent cure")
- Probability language: Using vague qualifiers ("common," "rare," "most men") for outcomes that hurt your case, and precise numbers for outcomes that help it
Why Quantification Threatens Certain Recommendations
This is the critical insight: when a clinician refuses to quantify outcomes, ask yourself which treatment recommendation their refusal protects.
Consider a surgeon's framing of erectile dysfunction (ED) after prostatectomy. The actual data shows:
- ED occurs in approximately 50–70% of men after prostatectomy, depending on age and baseline function
- ED often persists or worsens over time; recovery is incomplete in most men beyond age 60
- Medical management of post-surgical ED has lower efficacy than prevention
- In men with baseline excellent ED function, this represents a permanent loss
Now consider how these facts are typically communicated in a surgical consultation. A surgeon might say:
This statement is technically true and utterly misleading. The surgeon has:
- Named the side effect (satisfying bare minimum SDM)
- Used the qualifier "can occur" (suggests it's optional, not likely)
- Emphasized recovery ("many men recover") without quantifying it
- Minimized severity by framing it as manageable ("good options")
- Left the patient with the impression that ED is a small risk with good fixes
If the surgeon instead said: "Fifty to sixty percent of men your age experience erectile dysfunction after surgery. In most cases it is permanent despite medical or device management. If you have normal erectile function now, this is a significant quality-of-life change you should expect," the patient's decision calculus changes immediately. Suddenly, surgery doesn't look like a cure for cancer with a minor side effect—it looks like trading a curable cancer for a cure that leaves you with severe sexual dysfunction.
The surgeon won't say the second thing because it makes the recommendation harder to defend. The surgeon's refusal to quantify is information about their confidence in the recommendation, not about the complexity of the data.
Specialty-Specific Persuasion Patterns: The Smoking Gun
The Naser-Tavakolian analysis found distinct persuasive patterns by specialty:
| Specialty | Typical Persuasive Pattern | Data Emphasized | Data Omitted or Minimized |
|---|---|---|---|
| Urology (Surgery) | Cancer control narrative | Oncologic outcomes, cure rates, PSA recurrence | Incontinence and ED rates, long-term quality-of-life impact |
| Radiation Oncology | Organ preservation narrative | Cure rates without surgery, acute tolerance | Late toxicity (ED, incontinence, bowel dysfunction), long-term disease control in high-risk disease |
| Medical Oncology | Systemic burden narrative | Systemic therapy response, PSA reduction | Heterogeneity in outcomes, importance of localized disease control for patients with long life expectancy |
| Active Surveillance | Avoid-treatment narrative (when advocated) | Overtreatment risks, quality of life | Progression risk over time, genomic heterogeneity in metastatic potential |
Note that this isn't a list of lies. It's a list of selective truths. Each specialty is emphasizing data that exist and is downplaying data that also exist. The persuasion works because it's built on truths—just incomplete ones.
The Daskivich Catalog: What Omission Looks Like
Daskivich's analysis of actual consultation transcripts found concrete omission patterns:
- Erectile dysfunction was completely omitted in 15% of surgery consultations
- Urinary incontinence was completely omitted in 12% of surgery consultations
- When mentioned, side effects were described without incidence rates or timelines in the majority of cases
- Across all specialties, when side effects were discussed, they averaged at Level 3 granularity (vague generalization like "high risk") rather than Level 5–6 (quantified with timepoint, or individualized)
This is not accidental. Surgeons know about ED and incontinence. These are not obscure complications they forgot to mention. They are omitting or vaguely describing them because naming them precisely would make patients less likely to consent to surgery.
The Financial Incentive Layer
Beyond training culture, there are real financial incentives. A urologist in private practice who doesn't recommend surgery loses volume. A radiation oncology practice that doesn't convert patients to radiotherapy can't fill its treatment slots. These are not abstract incentives—they shape daily decision-making.
At academic centers, the incentives are slightly different but equally real: teaching hospitals need case volume for resident training, academic reputation is built on clinical outcomes (and clinicians select which outcomes to emphasize), and department revenue is generated by procedures. A surgeon at UCSD Moores Cancer Center is part of an institution that depends on volume. That shapes how neutrally they can discuss active surveillance alternatives.
This doesn't mean your oncologist is dishonest. It means their structural position creates unconscious bias. They have genuinely come to believe that their modality is best—not because they've carefully weighed all evidence, but because confirmation bias is powerful and their financial incentives align with their clinical recommendations. The brain does this automatically.
You cannot rely on individual clinician integrity to overcome structural incentives. You have to work around them.
How to Detect Persuasive Framing: A Patient's Tactical Guide
1. Vague Language for Data That Hurts Their Case
Listen for probability language rather than numbers:
- "Some men experience ED" = Likely >30% but they won't say it
- "Most men recover function" = Contradicts actual data; they're emphasizing exceptions
- "Incontinence is rare" = Means >10% but <50%; too high to mention precisely
Your counter: "I need the specific number, not a descriptor. What percentage of men my age, with my baseline function, experience [side effect] at 5 years?"
2. Contrast Asymmetry: Precision for Your Treatment, Vagueness for Alternatives
A surgeon might say:
Translation: Exact number for surgery, vague danger for radiation. If radiation were actually inferior, they could cite its numbers. They can't, so they use scary language instead.
Your counter: "What is the biochemical recurrence-free survival with radiation at 10 years for my stage and grade? I need comparable data, not contrasting rhetoric."
3. Temporal Sleight-of-Hand: Short-term vs. Long-term Swap
Surgeon: "Radiation has significant acute side effects during treatment. After that, most men do fine." (True but misleading: late toxicity rises over years.)
Radiation oncologist: "Surgery has immediate complications and permanent sexual dysfunction." (Also true, but emphasizes different timescale.)
Your counter: "I need side-effect rates at 1 year, 5 years, and 10 years for all modalities. Don't cherry-pick timescales."
4. Omission of the Competing-Risk Context
A clinician might discuss cancer outcomes without discussing life expectancy. Example:
Your counter: "How does my life expectancy compare to the time-to-progression with watchful waiting? Do I have time for this cancer to kill me, or will something else get me first?"
5. Appeal to Authority Instead of Data
"Our institute recommends..." "Experts agree..." "Current guidelines favor..." These are not arguments; they're appeals to tradition and consensus.
Your counter: "What is the evidence for that recommendation in patients like me? Can you walk me through the data?"
The CONVERGE-01 Context: Trial Recruitment as a Special Case
If you are enrolled in a clinical trial (such as CONVERGE-01 at UC San Diego Moores Cancer Center), be aware that trial clinicians face a dual loyalty: to your care, and to trial enrollment. These sometimes conflict.
Dr. Yu-Wei Chen and Dr. Rana McKay are excellent clinicians. But they are also running a trial that depends on patient enrollment. This creates pressure—not necessarily conscious—to frame the trial favorably and to minimize discussion of the control arm (conventional therapy).
For trial patients: comparing your trial treatment to the control requires even more disciplined questioning, because the default framing will emphasize trial benefits while softening discussion of control-arm outcomes.
Specific questions for a trial context:
- "If I were in the control arm, what would my median overall survival be, and with what quality of life?"
- "What percentage of patients in the trial experience grade 3+ hematologic toxicity, and how does that compare to historical controls?"
- "What is the dropout rate from the trial, and why do patients drop out?"
- "If the trial stops being beneficial at interim analysis, do I get stopped or continue the original assignment?"
- "Are there published results from the trial yet? Can I see them before deciding?"
These are not adversarial questions. They are the questions that convert a trial from "the doctor wants me to do this" to "I understand what I'm choosing between." Trial patients especially need this clarity, because they are assuming additional risk in exchange for potential benefit.
What to Do When a Clinician Won't Quantify
You will encounter resistance. Here's how to navigate it:
Stage 1: Direct Request
"I need a specific number, not a descriptor. In 100 men my age with my stage disease treated with [modality], how many experience [outcome] at [timeframe]?"
Most clinicians will provide a number here. The ones who don't are showing you something important.
Stage 2: Silence or Deflection
If they say "the data varies" or "it depends" or "there's a range," respond:
"Give me the range. What's the low estimate and the high estimate? What's the most likely estimate for someone in my demographic and baseline function?"
Stage 3: Institutional Appeal
If they still won't quantify, ask for data from their own institution:
"Do you track outcomes for your own patients? What are the ED rates in your surgery cohort at 5 years? What are the incontinence rates?"
Good cancer centers have this data. If they don't, that's a red flag about outcome tracking, not about data complexity.
Stage 4: Second Opinion
If a clinician becomes defensive about being asked for precision, get a second opinion from a different specialty. A surgeon should be willing to hear how a radiation oncologist discusses outcomes. An oncologist should be willing to hear how a urologist discusses local control. A clinician who is comfortable with your getting another opinion is someone who trusts their data.
Stage 5: Document Everything
Request that your consultation be recorded, or ask for a written summary that includes the specific numbers discussed. If the summary doesn't include the numbers you asked about, ask why. This creates accountability.
The Persuasion Is Not Personal; But Your Response Must Be
Important: The bias and persuasion described here is not personal dishonesty. Your urologist is not maliciously deceiving you. They are caught in a system that trains them to see their modality as best, gives them financial incentives aligned with that belief, and provides psychological justification (confirmation bias, training culture, peer reinforcement) for selective communication.
But the fact that it's systemic doesn't make it less true, and it doesn't make it less your responsibility to counter it. The system will not correct itself; clinicians are not trained in, rewarded for, or monitored for quality of SDM communication. You have to work around the system.
This requires:
- Skepticism: Assume that the first recommendation you receive is influenced by the recommender's specialty and incentives. Get at least one other perspective.
- Documentation: Insist on recorded consultations or written summaries with specific numbers. This creates accountability and gives you something to reference later.
- Precision: Ask for numbers, not descriptors. "Rare" and "common" are not data. Make the clinician choose between quantifying or admitting they can't.
- Patience: Good clinicians will answer these questions readily. Bad ones will become defensive or impatient. Both are information.
- Humility about Your Own Bias: You also have biases. You'll hear information that fits your prior beliefs more clearly than information that contradicts them. This is why getting multiple perspectives is not optional—it's the only way to correct for your own confirmation bias.
The Broader Picture: Why SDM Fails Systemically
This article has focused on clinician persuasion. But the failure of SDM is also structural:
- Time constraints: A 20-minute consultation is not enough to explain prognosis, competing risks, baseline function, and all treatment options with individualized outcomes. Clinicians rush. Rushing favors the simplest recommendation, which is usually the most common modality.
- Training deficits: Physicians are not trained in SDM communication. Medical education trains them to diagnose and recommend. Teaching someone to present balanced information runs counter to that training.
- Measurement absence: Clinicians are measured on clinical outcomes, not on SDM quality. There is no institutional pressure to quantify side effects or to avoid persuasive language.
- Patient variability: Some patients want direction ("tell me what to do"). Some want shared decision-making. Clinicians default to the direction-giving mode because it's simpler and more culturally normalized.
These structural problems won't be solved by individual patient advocacy. But individual patients can protect themselves by recognizing persuasive framing and refusing to accept it.
What Comes Next: The RCT on NLP Feedback
There is reason to believe this can change. A randomized controlled trial (NCT06856694) is now testing whether automated NLP-based feedback to clinicians improves their SDM communication. This trial will show whether clinicians who are given data on their own communication patterns change their behavior, and whether that change improves patient outcomes.
If the trial succeeds, it could lead to institutional implementation of communication auditing. That's not perfect—audit systems can be gamed—but it's better than the current system, where persuasion is invisible and unmonitored.
Until then, you are your own quality-control system.
Conclusion: You Cannot Outsource This Decision
Prostate cancer treatment is a consequential choice. The outcomes vary widely based on disease stage, baseline function, life expectancy, and patient values. No single modality is right for everyone. Yet the default in most clinical settings is that your clinician will recommend their modality, frame it persuasively, omit data that make it look worse, and call this "shared decision-making."
You cannot fix this clinician by clinician. But you can protect yourself by:
- Recognizing that persuasive framing is structural, not personal
- Demanding quantification instead of descriptors
- Getting multiple perspectives from different specialties
- Insisting on documentation of numbers discussed
- Understanding that a clinician's refusal to quantify is information about their confidence in the recommendation
Shared decision-making means you decide, not that you listen to someone else's decision disguised as your choice. The difference is precision.
Comments
Post a Comment